ALNY Stock Analysis: Alnylam Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 30.595m USD | 12M Return: -50% | US02043Q1076 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 442M
Qual. Beats: 0
Rev. Trend: 94.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Alnylam Pharmaceuticals is a U.S.-based biotechnology company founded in 2002 and headquartered in Cambridge, Massachusetts. It is a pioneer in RNA interference (RNAi)-based therapeutics, a drug-discovery platform recognized with the 2006 Nobel Prize in Physiology or Medicine, and operates as a fully integrated business spanning discovery, development, manufacturing, and global commercialization. The company markets several approved RNAi therapies-including ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, and Qfitlia-and earns additional royalty revenue through its collaboration with Novartis on Leqvio, used to lower LDL cholesterol in high-risk patients.
Alnylam sustains its pipeline by reinvesting revenues into a large, diversified portfolio of clinical-stage RNAi candidates targeting rare genetic diseases, cardiometabolic conditions, infectious diseases, and central nervous system disorders. Late-stage assets include Nucresiran for ATTR amyloidosis, Zilebesiran for hypertension, and Cemdisiran for complement-mediated diseases. The company has established development and commercialization partnerships with major pharmaceutical firms including Regeneron, Roche, Sanofi, Novartis, and Ionis, which is a typical structure in the biotech sector that helps share R&D costs and expand global reach.
- Amvuttra TTR franchise revenue accelerates with label expansions
- BridgeBio Attruby competition pressures Amvuttra market share
- Zilebesiran Phase 3 hypertension data readouts could unlock massive market
| Net Income: 808.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 19.78 > 1.0 |
| NWC/Revenue: 64.69% < 20% (prev 95.16%; Δ -30.48% < -1%) |
| CFO/TA 0.11 > 3% & CFO 634.5m > Net Income 808.0m |
| Net Debt (-1.10b) to EBITDA (1.15b): -0.95 < 3 |
| Current Ratio: 3.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (138.2m) vs 12m ago 6.61% < -2% |
| Gross Margin: 79.72% > 18% (prev 83.64%; Δ -3.92% > 0.5%) |
| Asset Turnover: 94.90% > 50% (prev 53.92%; Δ 40.98% > 0%) |
| Interest Coverage Ratio: 3.37 > 6 (EBIT TTM 1.10b / Interest Expense TTM 325.1m) |
| A: 0.56 (Total Current Assets 4.62b - Total Current Liabilities 1.51b) / Total Assets 5.56b |
| B: -1.14 (Retained Earnings -6.33b / Total Assets 5.56b) |
| C: 0.22 (EBIT TTM 1.10b / Avg Total Assets 5.06b) |
| D: 0.32 (Book Value of Equity 1.35b / Total Liabilities 4.20b) |
| Altman-Z'' = 1.75 = BBB |
| DSRI: 0.82 (Receivables 912.7m/567.1m, Revenue 4.80b/2.46b) |
| GMI: 1.05 (GM 83.64% / 79.72%) |
| AQI: 0.72 (AQ_t 0.04 / AQ_t-1 0.05) |
| SGI: 1.95 (Revenue 4.80b / 2.46b) |
| TATA: 0.03 (NI 808.0m - CFO 634.5m) / TA 5.56b) |
| Beneish M = -2.61 (Cap -4..+1) = A |
As of August 17, 2026, the stock is trading at USD 228.65 with a total of 1,507,930 shares traded. Over the past week, the price has changed by +4.31%, over one month by -19.25%, over three months by -20.13% and over the past year by -49.95%.
Current recommended Stop Loss: 212.70 (which is 7% or 1.2 ATR below the current price).
Alnylam Pharmaceuticals has received a consensus analysts rating of 4.23. Therefore, it is recommended to buy ALNY.
- StrongBuy: 15
- Buy: 7
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 372.3 | 62.8% |
P/E Trailing = 39.8345
P/E Forward = 26.3158
P/S = 6.3685
P/B = 22.5944
P/EG = 0.4344
Revenue TTM = 4.80b USD
EBIT TTM = 1.10b USD
EBITDA TTM = 1.15b USD
Long Term Debt = 1.01b USD (from longTermDebt, last quarter)
Short Term Debt = 45.9m USD (from shortTermDebt, last quarter)
Debt = 1.52b USD (from shortLongTermDebtTotal, last quarter) + Leases 256.4m
Net Debt = -1.10b USD (calculated: Debt 1.52b - CCE 2.62b)
Enterprise Value = 29.5b USD (30.6b + Debt 1.52b - CCE 2.62b)
Interest Coverage Ratio = 3.37 (Ebit TTM 1.10b / Interest Expense TTM 325.1m)
EV/FCF = 26.64x (Enterprise Value 29.5b / FCF TTM 1.11b)
FCF Yield = 3.75% (FCF TTM 1.11b / Enterprise Value 29.5b)
FCF Margin = 23.05% (FCF TTM 1.11b / Revenue TTM 4.80b)
Net Margin = 16.82% (Net Income TTM 808.0m / Revenue TTM 4.80b)
Gross Margin = 79.72% ((Revenue TTM 4.80b - Cost of Revenue TTM 974.3m) / Revenue TTM)
Gross Margin QoQ = 76.90% (prev 81.91%)
Tobins Q-Ratio = 5.31 (Enterprise Value 29.5b / Total Assets 5.56b)
Interest Expense / Debt = 21.33% (Interest Expense 325.1m / Debt 1.52b)
Taxrate = 7.49% (13.3m / 177.8m)
NOPAT = 1.01b (EBIT 1.10b * (1 - 7.49%))
Current Ratio = 2.85 (Total Current Assets 4.62b / Total Current Liabilities 1.62b)
Debt / Equity = 1.13 (Debt 1.52b / totalStockholderEquity, last quarter 1.35b)
Debt / EBITDA = -0.95 (Net Debt -1.10b / EBITDA 1.15b)
Debt / FCF = -0.99 (Net Debt -1.10b / FCF TTM 1.11b)
Total Stockholder Equity = 863.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.96% (Net Income 808.0m / Total Assets 5.56b)
RoE = 93.61% (Net Income TTM 808.0m / Total Stockholder Equity 863.1m)
RoCE = 58.48% (EBIT 1.10b / Capital Employed (Equity 863.1m + L.T.Debt 1.01b))
RoIC = 26.32% (NOPAT 1.01b / Invested Capital 3.85b)
WACC = 6.96% (E(30.6b)/V(32.1b) * Re(6.32%) + D(1.52b)/V(32.1b) * Rd(21.33%) * (1-Tc(0.07)))
Discount Rate = 6.32% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.15 | Cagr: 4.16%
[DCF] Terminal Value 77.97% ; FCFF base≈667.1m ; Y1≈764.8m ; Y5≈1.13b
[DCF] Fair Price = 134.8 (EV 16.9b - Net Debt -1.10b = Equity 18.0b / Shares 133.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.42 | # QB: 0
Revenue Correlation: 94.81 | Revenue CAGR: 42.58% | SUE: -0.25 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.32 | Chg30d=-3.87% | Revisions=-56% | Analysts=14
EPS current Year (2026-12-31): EPS=8.92 | Chg30d=-5.06% | Revisions=-35% | GrowthEPS=+75.5% | GrowthRev=+48.0%
EPS next Year (2027-12-31): EPS=12.59 | Chg30d=-5.40% | Revisions=-47% | GrowthEPS=+41.2% | GrowthRev=+26.9%
[Analyst] Revisions Ratio: -52% (up=9, down=32)